Published in Cell Death Dis on November 15, 2012
Chronic stress induces CD99, suppresses autophagy, and affects spontaneous adipogenesis in human bone marrow stromal cells. Stem Cell Res Ther (2017) 0.75
CD99-derived agonist ligands inhibit fibronectin-induced activation of β1 integrin through PKA/SHP2/ERK/PTPN12/FAK signaling pathway. Mol Cell Biol (2017) 0.75
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science (2009) 4.80
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene (1990) 3.74
CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol (2002) 3.01
Heat shock proteins as cellular lifeguards. Ann Med (1999) 2.09
Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 1.98
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene (2000) 1.57
Heat shock proteins--modulators of apoptosis in tumour cells. Leukemia (2000) 1.34
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones (2000) 1.28
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol (2007) 1.23
CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol (1997) 1.19
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene (2004) 1.12
Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood (1994) 1.10
Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood (2005) 1.05
Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res (1998) 1.05
Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study. Proteomics (2006) 1.04
Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep (2005) 1.03
Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol (2005) 1.02
RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival. Blood (2006) 0.95
Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol (1998) 0.94
CD99 isoforms expression dictates T cell functional outcomes. FASEB J (2002) 0.93
Arsenic trioxide induces Hsp70 expression via reactive oxygen species and JNK pathway in MDA231 cells. Life Sci (2005) 0.92
Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol (2006) 0.91
CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol (2001) 0.91
Engagement of CD99 triggers the exocytic transport of ganglioside GM1 and the reorganization of actin cytoskeleton. FEBS Lett (2003) 0.90
Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood (2008) 0.87
Selective protection by hsp 70 against cytotoxic drug-, but not Fas-induced T-cell apoptosis. Immunology (1999) 0.85
Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. J Leukoc Biol (2010) 0.84
HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate (2007) 0.84
CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol (1999) 0.84
Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-ALL at presentation or relapse. Eur J Haematol (2003) 0.81
Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis. Leuk Lymphoma (1998) 0.77
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia (2005) 3.09
Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med (1999) 1.26
PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia (2003) 0.95
Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia (2004) 0.93
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia (2011) 0.92
Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia (2011) 0.84
Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia (2007) 0.82
Development of a curative treatment within the AML-BFM studies. Klin Padiatr (2013) 0.82
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia (2012) 0.81
CD44 deficiency is a consistent finding in childhood Burkitt's lymphoma and leukemia. Leukemia (2007) 0.80
Quantification of CD34+ cells: comparison of methods. Transfusion (1997) 0.78
[Minimal metastatic and minimal residual disease in patients with Ewing tumors]. Klin Padiatr (1995) 0.75